Overview

Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of ethyl icosapentate in Chinese patients with severe hypertriglyceridemia.
Phase:
Phase 3
Details
Lead Sponsor:
Mochida Pharmaceutical Company, Ltd.
Collaborator:
Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
Treatments:
Eicosapentaenoic acid ethyl ester